Cipla Limited (CIPLA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Cipla Limited, explained in plain English.

• ▪Cipla Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪CIPLA closed at ₹1,376.00 on 30 October 2026.
• ▪Over the past year the shares are down 10.7%, trading between ₹1,165.70 and ₹1,593.30.
• ▪Reported fundamentals show return on equity of 8.33%, a net margin of 10.35%, debt to equity of 1.97.
• ▪Our transparent MaxGrade checklist scores it D (48/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 19.75% with a maximum drawdown of -22.35% and a beta of 0.54 against NIFTY 50.
• ▪Recent coverage: Cipla’s US recovery, biosimilar pipeline key to future growth prospects
• ▪Recent coverage: Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
• ▪Recent coverage: Q2 Results Live: L&T, Maruti Suzuki, Tata Steel, Cipla, SBI Life, Bajaj Auto, Indus Towers, Waaree Energies In Focus

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Figures from the current session. Market open.